Biocon sets July dividend date, shares trade steadily on NSE

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 20:41.

Biocon (INE376G01013) has its 2026 dividend schedule in place with a confirmed record date at the start of July. The Bengaluru-based pharma group’s shares trade on the NSE under the ticker BIOCON, and the current payout keeps the yield modest for investors. Choice India dividend overview

Dividend details and July record date

Biocon has declared a dividend of ?0.50 per share for 2026, according to a recent dividend update that lists the ex-dividend and record dates as 3 July 2026. Choice India dividend overview Registered shareholders who own Biocon shares on or before the record date are eligible to receive the payout in their bank accounts linked to their demat holdings.

The latest communication indicates that investors can expect the dividend payment to be credited within roughly 25 to 45 business days after the record date of 3 July 2026, in line with standard Indian market practice for corporate actions. Choice India dividend overview At a recent share price around the low ?420s, the cash distribution translates into a relatively low single-digit dividend yield.

Analyst and technical stance on the shares

On the technical side, Biocon’s NSE-listed shares show a Strong Buy signal based on daily indicators, with seven buy signals and only two sell signals in the latest technical summary. Investing.com technical analysis for Biocon As of 23 June 2026, the technical price is noted at ?423.20, up ?2.10 or 0.50 percent intraday.

The same technical snapshot highlights pivot levels around ?423.82 on Fibonacci metrics, suggesting that Biocon is trading close to important short-term reference points on the NSE for active traders. Investing.com technical analysis for Biocon For longer-term holders, the combination of a Strong Buy technical bias and a modest dividend stream underlines a mixed total-return profile with a clear focus on capital appreciation rather than income.

The product behind the stock

Biocon generates most of its revenue from biologics and biosimilars, including insulin and monoclonal antibody products that compete with global peers such as Novo Nordisk and Roche in diabetes and oncology segments. Biocon corporate overview The portfolio spans active pharmaceutical ingredients and finished-dose formulations that are supplied to regulated markets worldwide.

Where the stock trades today

Biocon shares (INE376G01013) most recently traded on the NSE at around ?423 per share in late June 2026, with the technical snapshot as of 23 June 2026, 12:26 GMT citing a price of ?423.20 in Indian rupees. Investing.com technical analysis for Biocon

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. All data are based on publicly available sources believed to be reliable at the time of writing.